Betulinic acid - Advanced Life Sciences

Drug Profile

Betulinic acid - Advanced Life Sciences

Alternative Names: ALS-357

Latest Information Update: 06 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Illinois at Chicago
  • Developer Advanced Life Sciences
  • Class Antineoplastics; Triterpenes
  • Mechanism of Action Apoptosis stimulants; Caspase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Malignant melanoma

Most Recent Events

  • 06 May 2011 Suspended - Phase-I for Malignant melanoma in USA (Topical)
  • 06 May 2011 Suspended - Preclinical for Malignant melanoma in USA (PO)
  • 28 Aug 2007 ALS 357 receives orphan drug status for topical treatment of metastatic melanoma in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top